Viewing Study NCT05471856

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:32 PM
Ignite Modification Date: 2026-02-22 @ 7:26 PM
Study NCT ID: NCT05471856
Status: RECRUITING
Last Update Posted: 2025-12-17
First Post: 2022-07-21
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
Sponsor: Boehringer Ingelheim
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Solid Tumors View
Keywords: